01—Abstract
Summary
Summary of the 10-K filed September 1, 2006. Cited figures are marked; the original filing is the authoritative source.
Cardinal Health Inc. reported record revenue of $81.4 billiona for the fiscal year ended June 30, 2006, a 10% increase year-over-year, driven by growth across all four reportable segments.
The company highlighted an 8% increase in operating earnings to $2.0 billionb and a 14% rise in diluted earnings per share from continuing operations to $2.90. A significant transition to a fee-for-service model in the Pharmaceutical Distribution segment was completed, which is expected to moderate earnings seasonality and volatility.
However, the company is also managing the impact of ongoing SEC and U.S. Attorney investigations, for which it has reserved $35 millionc, and significant shareholder litigation, though the ultimate outcome and financial impact are currently unpredictable. Despite these legal and regulatory challenges, the company continues to focus on operational improvements and strategic acquisitions, demonstrating resilience in its core distribution and services businesses.
02—Key points
Key Highlights
- Reported record revenue of $81.4 billion for FY 2006, a 10% increase from FY 2005.
- Operating earnings grew 8% to $2.0 billion, with diluted EPS from continuing operations up 14% to $2.90.
- Completed transition to a fee-for-service model in Pharmaceutical Distribution, aiming to reduce earnings volatility.
- Clinical Technologies and Services segment showed strong operating earnings growth of 56% due to revenue increases and efficiencies.
- The company is subject to ongoing SEC and U.S. Attorney investigations, with an agreement-in-principle for a potential $35 million settlement with the SEC.
- Significant shareholder and ERISA litigation is ongoing, with an uncertain but potentially material impact on future results.
- The company announced new share repurchase programs totaling $2 billion to be completed over fiscal years 2007 and 2008.
03—Questions
Frequently Asked Questions
What was Cardinal Health's financial performance in fiscal year 2006?
Cardinal Health reported record revenue of $81.4 billion, a 10% increase year-over-year. Operating earnings were $2.0 billion, up 8%, and diluted earnings per share from continuing operations increased by 14% to $2.90. The company also completed its transition to a fee-for-service model in its Pharmaceutical Distribution segment.
What significant legal or regulatory issues is Cardinal Health facing?
Cardinal Health is involved in ongoing investigations by the SEC and the U.S. Attorney's Office for the Southern District of New York concerning accounting and financial reporting matters. The company has reached an agreement-in-principle with the SEC staff for a potential settlement that includes a $35 million penalty, for which it has recorded reserves. Additionally, the company is subject to several significant shareholder and ERISA class-action lawsuits, the outcomes of which are uncertain and could materially affect future results.
How did the Pharmaceutical Distribution segment perform, and what significant changes occurred?
The Pharmaceutical Distribution and Provider Services segment saw revenue growth of 11% in FY 2006. Operating earnings were flat due to competitive pressures and a $31.8 million charge related to vendor credits. The segment completed its transition to a fee-for-service business model, which is expected to moderate earnings seasonality and reduce volatility going forward.
What is the company's capital allocation strategy regarding share repurchases?
Cardinal Health has demonstrated a commitment to returning capital to shareholders through share repurchases. In fiscal year 2006, the company repurchased approximately $3.5 billion of its shares. Following the fiscal year end, the company announced and began executing new share repurchase programs totaling $2 billion, expected to be completed over fiscal years 2007 and 2008.
04—Continue